Detalhe da pesquisa
1.
Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management.
J Am Acad Dermatol
; 90(5): 911-926, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37516356
2.
Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis.
J Am Acad Dermatol
; 90(5): 885-908, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37516359
3.
Patient Perspectives on Hidradenitis Suppurativa and Infertility: A Survey Study.
Dermatology
; 239(5): 732-737, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37385230
4.
Delayed diagnosis of DRESS syndrome in a patient with skin of color.
Dermatol Online J
; 29(1)2023 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37040918
5.
Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project.
Br J Dermatol
; 187(6): 927-935, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36056741
6.
Calciphylaxis: Part I. Diagnosis and pathology.
J Am Acad Dermatol
; 86(5): 973-982, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35114300
7.
Calciphylaxis: Treatment and outlook-CME part II.
J Am Acad Dermatol
; 86(5): 985-992, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35202773
8.
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.
J Am Acad Dermatol
; 86(5): 1092-1101, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33493574
9.
Dermatologic support for oncology: Quantifying the consultative services received by hospitalized oncology patients.
J Am Acad Dermatol
; 85(5): 1367-1368, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33951496
10.
Use of teledermatology by dermatology hospitalists is effective in the diagnosis and management of inpatient disease.
J Am Acad Dermatol
; 84(6): 1547-1553, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32389716
11.
High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa.
J Am Acad Dermatol
; 82(5): 1094-1101, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31589948
12.
Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists.
J Am Acad Dermatol
; 83(4): 1150-1159, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32569797
13.
Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project.
J Am Acad Dermatol
; 82(2): 366-376, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31279015
14.
Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults.
J Am Acad Dermatol
; 82(6): 1553-1567, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32151629
15.
Retrospective review of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis cases at a pediatric tertiary care institution.
Pediatr Dermatol
; 37(3): 461-466, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32058621
16.
Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017.
Exp Dermatol
; 28(1): 94-103, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30484907
17.
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.
J Am Acad Dermatol
; 81(1): 91-101, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30872149
18.
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.
J Am Acad Dermatol
; 81(1): 76-90, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30872156
19.
Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement.
Eur J Clin Pharmacol
; 75(8): 1135-1141, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30918988
20.
Correction to: Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement.
Eur J Clin Pharmacol
; 75(9): 1331, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31254013